Enfuvirtide
- Generic Name
- Enfuvirtide
- Brand Names
- Fuzeon
- Drug Type
- Biotech
- CAS Number
- 159519-65-0
- Unique Ingredient Identifier
- 19OWO1T3ZE
- Background
Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.
- Indication
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS.
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1)
T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 525
- Registration Number
- NCT00008528
- Locations
- 🇺🇸
Massachusetts Gen Hosp, Boston, Massachusetts, United States
🇺🇸Nicholas Bellos, Dallas, Texas, United States
🇺🇸Univ of Texas Med Branch, Galveston, Texas, United States
T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 525
- Registration Number
- NCT00021554
- Locations
- 🇳🇱
Natac Med Centre, Amsterdam, Netherlands
🇳🇱Univ Medical Center Utrecht, CX Utrecht, Netherlands
🇨🇭Univ Hosp Basel / Med Outpatient Dept, Basel, Switzerland
A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-11-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 68
- Registration Number
- NCT00002239
- Locations
- 🇺🇸
UCLA Care Ctr, Los Angeles, California, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
🇺🇸Pennsylvania Oncology and Hematology Associates, Philadelphia, Pennsylvania, United States
T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 52
- Registration Number
- NCT00022763
- Locations
- 🇺🇸
Children's Hosp Los Angeles, Los Angeles, California, United States
🇺🇸New York Hosp - Cornell / Program for Children with AIDS, New York, New York, United States
🇺🇸Bronx Lebanon Hosp Ctr, Bronx, New York, United States
HIV Maintenance Therapy With T-20 During HAART Interruption
- Conditions
- HIV Infection
- First Posted Date
- 2001-04-02
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 10
- Registration Number
- NCT00013884
- Locations
- 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.